Dubai moves forward with its Longevity Authority strategy, emphasising regulation, investment, and market activation

Dubai is in the process of creating a regulatory framework that will enable companies involved in longevity, wellness, and advanced healthcare to test their products and take them to market. A major milestone in achieving this objective was reached with the approval of the Dubai Longevity Authority‘s strategic plan and operational budget on September 27. This approval focused on accelerating regulatory development, pilot implementation, and market activation. Additionally, the plan was approved by Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum following the authority’s first board meeting.

Established under Law No. 17 of 2026, the authority has a wide-ranging role that includes everything from research and clinical trials to manufacturing and patient care. The initial announcement emphasised that regulations will be tailored to the varying risks posed by different therapies and innovations and developed in collaboration with organisations like the Dubai Health Authority, Dubai Health, Dubai Municipality, and Dubai Future Foundation.

This approach suggests that Dubai is aiming to cultivate the skills necessary to create and deliver health innovations locally. Since research, production, and clinical services each need their own types of expertise, facilities, and management, connecting these areas could help companies grasp how an innovation moves from concept to real-world application, including the evidence and resources that will be necessary throughout the process.

For instance, a business looking to conduct a clinical study needs to understand if its results could support a future application for producing or selling its product. Clarifying these expectations early on can greatly affect the study design, the selection of research partners, and the financial resources required before it can begin commercial operations.

Notably, the ageing population serves as a compelling reason to pursue this work. The World Health Organization estimates that by 2030, 1 in 6 people around the globe will be aged 60 or older. It also cautions that while lifespans are increasing, this doesn’t necessarily mean individuals will enjoy more years of good health. This emphasises the critical need to maintain the abilities that allow people to carry out daily activities and remain engaged in life.

A commercially viable response to these needs requires businesses to identify specific benefits and determine how these will be measured. A service aimed at facilitating independent living must demonstrate its effectiveness within that context. Conversely, a proposed clinical intervention would raise different considerations regarding safety, effectiveness, and appropriate utilisation. Treating these activities as interchangeable could complicate customer and investor assessments of what a company genuinely offers.

Dubai’s proposed Minimum Viable Product programme aims to provide a supervised environment in which selected innovators can test and develop their offerings. According to the announcement made in September, the authority is also setting the direction for activity-based licensing, minimum standards, and enforcement. The programme is still under development, and the announcement does not confirm that a general application process is currently open.

Evaluating whether participation in this programme could support a viable business necessitates that companies and investors address several critical questions:

• Eligibility and Testing Requirements: The eventual entry criteria will determine whether the programme aligns with a company’s offering and stage of development, while testing requirements will shape its staffing, budget, and timeline.
• Progression Beyond a Pilot: Companies must understand what successful participation entails and what additional requirements must be met before manufacturing or delivering an offering commercially.
• Commercial Feasibility: A business must ascertain who will purchase its product or service, how delivery will be financed, and whether the expected revenue will cover operating costs.

Dubai already fosters scientific exchange surrounding these issues. Dubai Science Park and the Geneva College of Longevity Science partnered to organise a second longevity symposium, held in February 2026, which convened experts across science, healthcare, and policy. Such events provide a platform for identifying collaborators, although the utility of these connections will depend on the ensuing work.

Partnership decisions should reflect the specific objectives a company aims to achieve and the expertise necessary to accomplish them:

• Research Institutions could assist in designing studies and assessing whether an intervention yields its intended effects.
• Healthcare Providers could evaluate how a proposed product or service fits into existing care frameworks and the implications for delivery.
• Manufacturing Partners could appraise production requirements, ensure consistency, and determine the capacity needed to supply the market.

Clearly defining each partner’s responsibilities, resources, and expected contributions prior to committing funds will provide the business with a more solid foundation for planning and evaluating the collaboration.

Getting into Dubai’s growing business scene means making some big decisions about how committed you want to be while developing your operational strategy. Companies can initiate this process by evaluating local capabilities, establishing the ownership and permitted use of collaboratively developed work, and identifying the personnel or facilities required for their activities. After that, they can tie their commitments to specific milestones, like confirming what’s required, agreeing on a research plan, or setting up a viable delivery method.

Anticipated announcements related to licensing and supervised testing are set to allow businesses to examine the authority’s strategies with more clarity. For companies contemplating a move at this point, this interval offers the chance to evaluate if their evidence, financial resources, and delivery capabilities align with their planned initiatives. Such groundwork will establish a stronger foundation for deciding when and how significantly to invest.